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ABSTRACT
Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality worldwide.
The treatment of CAP has been complicated by several factors, including the expanding spectrum of
causative organisms and the rising prevalence of antibiotic resistance among respiratory pathogens.
Initial antimicrobial treatment for patients with CAP is usually selected empirically and should provide
appropriate coverage against the most common causative organisms, including resistant strains.
Respiratory ﬂuoroquinolones, such as levoﬂoxacin, are the only antimicrobials that are highly active
against the pathogens most frequently implicated in CAP, including macrolide-resistant and penicillin-
resistant pneumococci, Haemophilus inﬂuenzae, Legionella spp., and atypical agents. This paper reviews
recent studies involving adult patients with CAP that suggest that levoﬂoxacin, as compared with other
conventional antibiotic treatments, may be associated with better clinical outcomes.
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INTRODUCTION
Community-acquired pneumonia (CAP) remains
the leading cause of death due to infection in
developed countries [1]. Although mortality
decreased precipitously with the advent of anti-
microbial therapy, since 1950 rates have stabilised
at c. 12 )14% [2–4]. Nowadays, the management
of CAP continues to represent a major challenge
for physicians. It is becoming progressively com-
plicated due to several factors, e.g., the expanding
spectrum of causative organisms, the rising pre-
valence of resistance to antimicrobial agents, the
increasing population of patients of advanced age
and with comorbidities, and the interest in redu-
cing the number of unnecessary hospitalisations
[5,6]. All these factors have led to vigorous debate
regarding the efﬁcacy of different approaches to
management. In fact, wide variations can be seen
among current guidelines for CAP with regard to
antibiotic choice [7].
Perhaps due to the fact that differences in the
clinical efﬁcacy of antimicrobials are difﬁcult to
demonstrate, discrimination between ‘good’ and
‘bad’ antimicrobials based on clinical outcomes
alone is not easy [8]. Commonly, target sample
sizes are calculated on the assumption that the
test agent and the agent with which it is
compared will produce the same rates of cure
[9]. In fact, according to The European Agency
for the Evaluation of Medicinal Products
(EMEA), each indication of an antimicrobial
should be supported by at least one randomised
and double-blind trial powered to show at least
non-inferiority to an acceptable, active compar-
ative regimen or superiority to placebo (when-
ever it is considered to be possible) [10].
Obviously, it is not considered ethical to use a
placebo control in studies evaluating the efﬁcacy
of an antimicrobial for treatment of CAP. In
mild to moderate CAP, there may be several
reasons for the difﬁculty of ﬁnding differences
among antimicrobials. Trials routinely exclude
patients with suspected resistant pathogens and
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with severe disease, some trials are undertaken
in places with low prevalence of resistance, and
there is a high rate of spontaneous cure in some
community-acquired respiratory tract infections,
including CAP. Moreover, in cases of severe
pneumonia, mortality could be an insensitive
measure of antibiotic efﬁcacy, as the rate of
early mortality associated with pneumonia
seems to be unaffected by antimicrobial therapy
[11–13].
Recent studies have revealed how treatment
with a respiratory ﬂuoroquinolone, particularly
levoﬂoxacin, can inﬂuence clinical outcomes in
CAP. In this paper we review those studies and
discuss the current role of levoﬂoxacin in the
treatment of CAP.
SELECTION OF THE ‘ IDEAL’
ANTIBIOTIC FOR CAP
Antimicrobial treatment for patients with CAP
is usually selected empirically after evaluation
of the most likely aetiology and taking into
account the prevalence of antibiotic resistance
among the most frequently causative organisms.
The ﬁrst consideration when selecting an anti-
biotic for the treatment of CAP is the antibiotic
spectrum [7], which should include the most
common causative pathogens. Streptococcus pneu-
moniae accounts for most cases of CAP in all
groups of patients, whether treated on an
outpatient basis or admitted to the hospital,
including those who are admitted to the inten-
sive care unit (ICU)[4,14]. In hospitalised pati-
ents, S. pneumoniae causes between 20 and 60%
of all cases of CAP [15]. For many years it has
been assumed that the aetiology of those pneu-
monias in which it was not possible to identify
any pathogens had a distribution similar to
those that were correctly diagnosed. However,
in recent studies carried out in inpatients with
CAP, in which new techniques to establish
aetiology were used, a high proportion of
subjects whose disease was without an identi-
ﬁed cause in fact had a pneumococcal infection
[16–18]. This indicates that the prevalence of
pneumococcal pneumonia could be underesti-
mated in most studies. In addition, S. pneumo-
niae is also the most important pathogen in
terms of mortality [19]. Legionella accounts for
up to 16% of cases of CAP, and in numerous
observational studies it is among the top four
microbial reasons for hospitalisation due to CAP
[20], being particularly frequent among patients
requiring ICU admission [21,22]. Mortality rates
associated with Legionella CAP range from 5 to
25% among immunocompetent hosts, and even
higher among the immunosuppressed [23,24].
The classic risk factors for legionnaires’ disease
include cigarette smoking, chronic lung disease,
and immunosuppression; the disease most fre-
quently occurs in the elderly [20]. It is import-
ant to emphasise that up to 34% of the patients
do not have any of these risk factors, suggesting
the need to cover atypical agents while selecting
an antimicrobial for the empirical treatment of
CAP [25]. The frequency of other atypical agents
(Mycoplasma pneumoniae, Chlamydophila pneumo-
niae) in patients with CAP is not clear, with
varying reports on their incidence, probably due
to the difﬁculty of reliably detecting these
organisms [26]. M. pneumoniae is especially
frequent in young patients (mainly those under
20 years old), while C. pneumoniae affects mainly
young patients as well as adults with underly-
ing diseases. Haemophilus inﬂuenzae and
Moraxella catarrhalis are more common in elderly
patients with COPD and in smokers, accounting
for 3–10% of CAP episodes [15]. Some patients
with CAP may have a mixed infection involving
both typical and atypical pathogens or even a
virus (e.g., inﬂuenza virus) [4], although the
incidence and clinical relevance of such co-
infection are not well known.
It is important to know what to include in
empirical CAP therapy, as well as what does not
need to be covered [7], at least for patients who
are not admitted to the ICU. Aerobic Gram-
negative bacilli such as Klebsiella spp. (1.2% of
2458 cases of CAP) and Escherichia coli (0.8%) are
infrequently causal agents of CAP outside the
ICU [27]. Pseudomonas aeruginosa is quite infre-
quently a causal agent, accounting for 0.5% of
nonsevere cases with an aetiological diagnosis
and 3.8% of severe cases [27], and occurr almost
exclusively in patients with cystic ﬁbrosis or
extensive bronchiectasis. Staphylococcus aureus
CAP occurs mainly as a complication of inﬂuenza.
In summary, pneumococcus, Chlamydophila
spp., and M. pneumoniae are the most frequent
agents in cases treated on an outpatient basis,
and pneumococci, atypical pathogens (including
Legionella spp.) and H. inﬂuenzae are the main
causative agents in hospitalised patients, whereas
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pneumococcus is the predominant pathogen in
patients with severe CAP, followed by Legionella
spp. and H. inﬂuenzae and other Gram-negative
bacilli [4,28,29].
Regarding the prevalence of resistance, a
Spanish multicentre study that included 2721
strains isolated from patients with lower res-
piratory tract infections (the SAUCE project)
found a prevalence of resistant S. pneumoniae of
22% for penicillin (with an additional 24% of
intermediate resistance), 0.4% for cefotaxime
(plus 2.9% of intermediate resistance), 4.4%
for amoxicillin and amoxicillin-clavulanate (plus
3.4% of intermediate resistance), 25.6% for
cefuroxime-axetil (plus 7.0% of intermediate
resistance), 34.5% for erythromycin, clarithro-
mycin, and azithromycin, and 1.2% for levoﬂ-
oxacin (plus 0.4% of intermediate resistance)
[30,31]. Among the newest antimicrobial agents,
amoxicillin-clavulanate 2000 ⁄ 125 mg sustained-
release and cefditoren offer appropriate cover-
age against S. pneumoniae. Telithromycin also
shows good antimicrobial activity for pneumo-
cocci, with about 99% of strains susceptible
[32].
The prevalence of resistance among penicillin-
nonsusceptible pneumococci to macrolides
reached 60%, compared with 15% among peni-
cillin-susceptible strains [30]. In H. inﬂuenzae,
nearly all strains are susceptible to cefotaxime,
cefuroxime, conventional and sustained-release
formulations of amoxicillin-clavulanate [30], cef-
ditoren [33] and levoﬂoxacin [33]. Erythromycin
is relatively inactive against H. inﬂuenzae. Clarith-
romycin also has relatively limited in-vitro activ-
ity against H. inﬂuenzae, whereas azithromycin is
the most active macrolide in vitro against this
pathogen [34]. In any case, no macrolide should
be used in monotherapy to treat a CAP caused by
H. inﬂuenzae. Telithromycin does not improve the
activity of the macrolides against H. inﬂuenzae.
With respect to atypical pathogens, all b-lactams
are inactive against all strains of M. pneumoniae
and C. pneumoniae, and they are ineffective in the
treatment of Legionella pneumonia. Macrolides,
telithromycin, and ﬂuoroquinolones are active
against atypical pathogens, although it is import-
ant to point out that ﬂuoroquinolones are bacte-
ricidal whereas macrolides are primarily
bacteriostatic. Against Legionella spp., levoﬂoxacin
and gemiﬂoxacin appear to be the most active
ﬂuoroquinolones [35,36].
ANTIBIOTIC RESISTANCE
POTENTIAL
A signiﬁcant factor that should be taken into
account when selecting an antimicrobial therapy
is the potential to select for resistance. The
association between community use of certain
antibiotics and the development of resistance in
S. pneumoniae has been widely demonstrated
[37–40]. It is important to note that not all drugs
have the same capacity to select for resistance, nor
are all microorganisms affected in the same way.
Penicillin resistance related to widespread use
has been associated with trimethoprim-sulfa-
methoxazole, tetracycline, oral cephalosporins,
and macrolide use [41], while it does not seem
to be related to the use of amoxicillin-clavulanate
or the respiratory ﬂuoroquinolones. Despite
b-lactams being consumed much more than
macrolides [42], some studies suggest that the
overall responsibility for macrolide resistance,
and even for penicillin resistance, lies much more
with the macrolides, and especially with long-
acting macrolides [43].
Among the ﬂuoroquinolones, levoﬂoxacin and
moxiﬂoxacin have low resistance potential.
Despite the use of a high volume of these ﬂuoro-
quinolones over the past years, the prevalence of
resistance of S. pneumoniae to them remains low
[7]. This could be due to low frequencies of
spontaneous mutation to ﬂuoroquinolone resist-
ance during therapy with levoﬂoxacin and mox-
iﬂoxacin [44]. Studies conducted in patients with
exacerbations of chronic bronchitis indicate that
resistance to levoﬂoxacin does not emerge rapidly
among strains of S. pneumoniae during therapy
with this agent [45]. What is more, increases in
respiratory ﬂuoroquinolone resistance are prob-
ably related to the increased use of certain non-
respiratory ﬂuoroquinolones (e.g., ciproﬂoxacin),
that have only marginal activity against S. pneu-
moniae [46,47]. Results from a study performed by
Chen et al. in Canada showed an increase in
ﬂuoroquinolone-resistant S. pneumoniae associated
with an increase in ﬂuoroquinolone usage.
Ciproﬂoxacin was the predominant ﬂuoroquino-
lone used during the study period [46]. In the
United States, from the 1998–99 season to the
2001–02 season, the prevalence of azithromycin
resistance increased from 4.8 to 27.5%, the preval-
ence of penicillin resistance increased from 3.7 to
18.4%, and the prevalence of ceftriaxone resistance
4 Clinical Microbiology and Infection, Volume 12 Supplement 3, 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 3), 2–11
increased from 0.5 to 1.7%, whereas the preval-
ence of levoﬂoxacin resistance increased from 0.3
to 0.9% [48].
Pneumococcal time-kill studies with levoﬂoxa-
cin, gatiﬂoxacin, and moxiﬂoxacin in a pharmac-
odynamic model have demonstrated that these
three agents possess equal bactericidal activity
and are equally effective in preventing the devel-
opment of resistance, as the lower in-vitro MICs
for gatiﬂoxacin and moxiﬂoxacin are offset by the
higher serum and tissue levels of levoﬂoxacin
[49]. In this study, ciproﬂoxacin did not exhibit
rapid killing and it selected for resistance faster
than the other three agents. Several studies have
been conducted with different respiratory ﬂuor-
oquinolones in order to evaluate their abilities to
select for resistant strains of S. pneumoniae. The
results of these studies were not conclusive as to
which drug has the lowest potential to select
resistant mutants [50,51].
In regard to the intestinal ﬂora, all of the
ﬂuoroquinolones have similar activity against
E. coli. Hence, the potential of each ﬂuoro-
quinolone to select for resistance depends on its
pharmacology. Intestinal excretion rates are 20–
35% for ciproﬂoxacin and 25% for moxiﬂoxacin,
compared with 4% for levoﬂoxacin [52]. If the
alteration of the intestinal ﬂora and the capacity
to select for resistance depend on exposure to
the antibiotic in the intestinal tract, ciproﬂoxacin
and moxiﬂoxacin have greater potential than
levoﬂoxacin to select for resistant strains of
intestinal, Gram-negative pathogens. Addition-
ally, the use of moxiﬂoxacin for respiratory
infections exposes bacteria in the intestinal tract
to a ﬂuoroquinolone with greater activity
against Bacteroides fragilis and other intestinal
anaerobes than levoﬂoxacin [53].
Clinical efﬁcacy of levoﬂoxacin against drug-
resistant S. pneumoniae (DRSP)
S. pneumoniae not only is the most common
causative pathogen of CAP, but also tends to be
associated with more severe disease than that
caused by other pathogens [2,54]. Two-thirds of
the fatal outcomes associated with CAP occur
among patients with disease due to S. pneumoniae
[55]. The increasing prevalence of resistance to
penicillin and other drugs among S. pneumoniae
has considerably complicated the empirical treat-
ment of CAP [11].
The clinical relevance of DRSP remains a matter
of some debate. Data supporting the clinical
relevance of penicillin- and especially macrolide-
resistant S. pneumoniae are increasingly appearing
in the literature [11]. Van Kerkhoven et al. [56]
reviewed 136 medical charts from patients with
pneumococcal bacteraemia who were admitted to
hospitals in Belgium during a 3-year period, to
determine the reasons for treatment failure. They
found that among the 136 pneumococcal isolates,
10.3% were nonsusceptible to penicillin and
24.3% were nonsusceptible to erythromycin, and
they concluded that the presence of macrolide
resistance is clinically relevant and leads to
treatment failure, whereas suboptimal dosing
may explain breakthrough pneumococcal bacter-
aemia in b-lactam-treated patients.
Feikin et al. [57] evaluated mortality rates asso-
ciated with 5837 cases of invasive pneumococcal
pneumonia, and they found that patients infected
with penicillin-resistant pneumococci (MIC ‡ 4
mg ⁄L) had more than seven times the risk of
death, compared with patients infected with
penicillin-susceptible pneumococci, when the ﬁrst
4 days of hospitalisation were excluded from
analysis. The mortality rate was also increased
among patients infected with pneumococcal iso-
lates with cefotaxime MICs of ‡ 2 mg ⁄L. How-
ever, the analysis did not explore the potential
impact of discordant therapy on outcome. This
was explored by Roso´n et al. [58] who observed
that discordant antimicrobial therapy is a less
frequent cause of failure. The presence of an
uncovered pathogen was the cause of early failure
in 16 of 81 patients, Legionella being the pathogen
most frequently associated with discordant ther-
apy. Drug-resistant S. pneumoniae was not inde-
pendently associated with early failure, and no
failures were attributable to resistance to b-lac-
tams. Regarding mortality, in two studies of
bacteraemic pneumococcal pneumonia [59,60] no
difference in mortality was found between those
patients with susceptible and those patients with
nonsusceptible pneumococci after control for age,
underlying disease, and severity of illness on
presentation. In these analyses, those patients
infected with pneumococci highly resistant to
penicillin (CMI ‡ 4 mg ⁄L) were not evaluated
independently.
Several cases of breakthrough pneumococcal
bacteraemia have been reported among patients
treated with macrolides. Lonks et al. [61]
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conducted a matched case–control study of
patients with bacteraemic pneumococcal infection
at three US centres and one Spanish centre. Their
data show that development of breakthrough
bacteraemia during macrolide or azithromycin
therapy is more likely to occur among patients
infected with an erythromycin-resistant pneumo-
coccus. Their study also demonstrated that low-
level, as well as high-level, resistance caused
therapy failure.
Among the ﬂuoroquinolones, levoﬂoxacin is
effective against penicillin-resistant S. pneumoniae.
It is also highly effective in the treatment of
macrolide-resistant pneumococcal CAP [62].
Despite the high activity of these antimicrobials
against pneumococci, breakthrough bacteraemia
has also been documented to occur with ﬂuoro-
quinolone therapy, mainly with ciproﬂoxacin and
levoﬂoxacin [63–65]. Of the cases reported, most
patients had been exposed to quinolones several
days or weeks before the CAP episode. Therefore,
ﬂuoroquinolones should not be administered as
empirical therapy for patients with CAP who
have recently received any drug of this class.
Results from a cumulative review of nine
completed phase III and IV trials evaluating
levoﬂoxacin in the treatment of CAP demonstra-
ted that levoﬂoxacin is very effective in the
treatment of CAP-associated pneumococcal bac-
teraemia, including disease due to penicillin- and
macrolide-resistant strains [66]. In this report,
outcomes of 497 microbiologically evaluable
patients with pneumococcal CAP were reviewed.
The overall post-therapy clinical success (cure
plus improved condition) rate was 95.0%. The
overall clinical success rates for patients with CAP
due to penicillin-resistant or macrolide-resistant
S. pneumoniae were 94.7% (18 of 19 patients) and
96.9% (31 of 32 patients), respectively. Of the 497
patients, 108 had a blood sample obtained at
admission that yielded S. pneumoniae on culture.
Ninety-eight (90.7%) of the 108 patients with
bacteraemia were considered to be clinically
cured or improved after levoﬂoxacin therapy.
Clinical success rates for bacteraemic patients
with macrolide- or penicillin-resistant S. pneumo-
niae were 83.3% (ﬁve of six patients) and 100%
(six of six patients), respectively. The microbiolo-
gical eradication rate in patients with pneumo-
coccal bacteraemia who had a known outcome
was 91.4% (96 of 105 patients). Eradication rates
in patients with bacteraemia caused by macrolide-
or penicillin-resistant pneumococcus were identi-
cal to the clinical rates. The mortality rate in this
population was < 1%. This study suggests that
levoﬂoxacin monotherapy can be an effective
choice for the treatment of CAP-associated pneu-
mococcal bacteraemia, including cases caused by
penicillin- and macrolide-resistant strains.
CLINICAL EFFICACY OF
LEVOFLOXACIN AGAINST
LEGIONELLA
In the past, erythromycin was for many years
the recommended treatment for patients with
legionnaire’s disease. Currently, most guide-
lines recommend azithromycin, or a respiratory
ﬂuoroquinolone for the treatment of Legionella
pneumonia [4,14], due to the fact that these anti-
microbials have been shown to be safe and more
effective than erythromycin [20]. Indeed, ﬂuoro-
quinolones have been shown to be better than
erythromycin in inhibiting the intracellular growth
of Legionella pneumophila, both in vitro and in animal
models [67–69].
Recently, two studies comparing levoﬂoxacin
vs. macrolides in the treatment of legionnaire’s
disease have been published. Both studies were
carried out in Spain. In the ﬁrst one, Mykietiuk
et al. [70] selected 139 cases of L. pneumophila
pneumonia for observational review, from a
prospective series of 1934 cases of CAP. One
hundred and twenty patients (86.3%) received an
appropriate initial therapy, with 80 receiving
macrolides (i.e., erythromycin or clarithromycin)
and 40 receiving levoﬂoxacin. Patients who were
treated with levoﬂoxacin reached defervescence
(2.0 vs. 4.5 days; p < 0.001) and clinical stability
(3 vs. 5 days; p ¼ 0.002) sooner. The median
length of hospital stay was 8 days in patients
who received levoﬂoxacin and 10 days in those
who received macrolides (p ¼ 0.014). No differ-
ences in the development of complications or the
case–fatality rate were observed. These data
suggest that levoﬂoxacin produces a more rapid
clinical response than older macrolides, allowing
a shorter hospital stay. The second study, per-
formed by Bla´zquez et al. [71], was an observa-
tional, prospective, nonrandomised study
involving 292 patients with CAP due to Legionella
during an outbreak in Murcia. Of 254 evaluable
patients, 67 received macrolides (clarithromycin
and azithromycin) and 187 were treated with
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levoﬂoxacin. Clarithromycin was used in all
patients with severe pneumonia. There were no
signiﬁcant differences in clinical outcomes among
the groups of patients with mild-moderate pneu-
monia (Fine class £ 3), but in patients with severe
pneumonia (Fine class ‡ 4), levoﬂoxacin was
more effective. The levoﬂoxacin treatment group
had fewer complications compared with the
macrolide treatment group (3.4% vs. 27.2%;
p ¼ 0.02) and shorter mean hospital stays
(5.5 days vs. 11.3 days; p ¼ 0.04). This study also
showed that adding rifampin to levoﬂoxacin
therapy provides no additional beneﬁt. Moreover,
the duration of fever, rate of complications,
and length of hospital stay were signiﬁcantly
increased in patients who received rifampin,
although this difference was probably a conse-
quence of differences in the severity of illness
among patients in each treatment group (despite
both groups having similar prognostic scores).
In another study performed through six clinical
trials encompassing a total of 1997 patients, data
were analysed to determine the efﬁcacy of levo-
ﬂoxacin in treating patients with CAP due to
Legionella. In this study, Yu et al. [25] reported a
successful experience with levoﬂoxacin therapy in
75 hospitalised and ambulatory patients. More
than 90% of mild-to-moderate and severe cases of
Legionella infection resolved clinically at the post-
therapy visit (2–14 days after treatment termin-
ation). No deaths were reported.
INFLUENCE OF LEVOFLOXACIN
TREATMENT ON OUTCOMES IN
PATIENTS WITH CAP
Differences in clinical efﬁcacy among antimicro-
bials are difﬁcult to demonstrate due to several
factors previously discussed. Nevertheless, some
studies suggest the superiority of levoﬂoxacin
monotherapy when compared with other stand-
ard regimens. The study by File et al. [72] was the
ﬁrst to demonstrate the superior activity of
levoﬂoxacin monotherapy for adults with CAP
in comparison with control patients who received
ceftriaxone and ⁄ or cefuroxime axetil with or
without erythromycin. Clinical success at 5–
7 days post-therapy was signiﬁcantly higher for
the levoﬂoxacin group compared with the ceftri-
axone and ⁄ or cefuroxime axetil group (96%
of 226 levoﬂoxacin recipients vs. 90% of 230
cephalosporin recipients; 95% CI, )10.7% to
)1.3%). Among patients with the ‘typical patho-
gens’ S. pneumoniae and H. inﬂuenzae, the overall
microbiological eradication rates were 98% and
85%, respectively (95% CI, )21.6% to )4.8%).
The pathogen was eradicated from 100% of the
levoﬂoxacin recipients with H. inﬂuenzae infec-
tion, but from only 79% of the cephalosporin
recipients (95% CI, )39.2% to )2.5%). The overall
clinical success for patients with atypical agents,
including C. pneumoniae, M. pneumoniae, and
L. pneumophila was 99% among those given
levoﬂoxacin and 94% among those given cepha-
losporin, with or without erythromycin. The
investigators concluded that levoﬂoxacin was
superior to ceftriaxone and ⁄ or cefuroxime axetil
for treatment of adults with CAP.
Several factors related both to patient charac-
teristics and clinical practices have been associ-
ated with increased or decreased mortality. Most
of them are patient factors, which unfortunately
cannot be modiﬁed. These factors include increas-
ing age, alcohol consumption, the presence of
bacteraemia, factors revealed by radiographic or
laboratory ﬁndings, several comorbid conditions,
and signs and symptoms such as dyspnea, chills,
altered mental status, hypothermia or hyperther-
mia, tachypnea and hypotension (diastolic and
systolic), and functional status [4,13,34]. Apart
from patient factors, there are aspects of care and
physician-related factors that also contribute to
mortality, some of which can be modiﬁed. Among
these, adequate antibiotic treatment at admission
can have an important inﬂuence on mortality. In
this regard, Querol et al. [73] have recently pub-
lished a prospective observational cohort study of
459 patients that was designed to compare the
effectiveness of levoﬂoxacin in single therapy
with the combination of ceftriaxone plus clarith-
romycin in the treatment of moderate to severe
CAP. Two hundred and ﬁfty-nine patients were
treated with levoﬂoxacin in monotherapy (500 mg
once a day) and 209 with the combination of
ceftriaxone plus clarithromycin (2 g once a day
and 500 mg every 12 h, respectively). Fifteen (6%)
patients died in the group treated with levoﬂoxa-
cin monotherapy and 25 (12%) in the group
treated with ceftriaxone plus clarithromycin
(p ¼ 0.024). The mortality differences between
the two treatment groups, adjusted by the Pneu-
monia Severity Index (PSI) score, revealed an
odds ratio (OR) of 0.39 (95% CI, 0.17–0.87). There
were also statistically signiﬁcant differences with
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regard to the frequency of patients who devel-
oped acute respiratory failure due to progression
of the pneumonia after admission and to the
number of patients with exacerbation of their
underlying disease. Both complications were
more frequent in patients who received ceftriax-
one plus clarithromycin than in those who were
treated with levoﬂoxacin (p ¼ 0.02 and p ¼ 0.038,
respectively). The results of this study suggest
that levoﬂoxacin might be superior to the combi-
nation of ceftriaxone and clarithromycin in the
treatment of patients with CAP requiring hospi-
talisation. It should be taken into account that
these results were not from a randomised trial,
and as with any observational study, there is
potential for confounding.
Previously, a population-based, retrospective
study found that ﬂuoroquinolone monotherapy
was associated with increased survival compared
with b-lactam monotherapy in patients requiring
hospitalisation [74], although these data should be
interpreted with caution, as the number of
patients included was small.
Marrie et al. [13] carried out a prospective
observational study involving more than 3000
patients to determine factors inﬂuencing in-hos-
pital CAP mortality. They found that treatment
with levoﬂoxacin in monotherapy was associated
with a decreased risk of late mortality (> 5 days).
In a prospective, multicentre cohort study of
1424 patients undertaken to identify risk factors
for treatment failure and to determine the impli-
cations of treatment failure for outcomes, Mene´n-
dez et al. [75] found that initial treatment with
ﬂuoroquinolones (levoﬂoxacin in 89.5% of the
cases) was independently associated with a lower
risk of treatment failure. Mortality was signiﬁ-
cantly higher in patients with treatment failure
(25% vs. 2%); in other words, the failure of
empirical treatment increased CAP mortality
11-fold after adjustment for risk class.
Besides mortality, other outcomes can also be
inﬂuenced by the type of antibiotic therapy. The
CAP intervention trial assessing levoﬂoxacin
(CAPITAL) [76] is a multicentre, controlled
clinical trial with cluster randomisation to deter-
mine if the use of a critical pathway improves
the efﬁciency of treatment. The critical pathway
includes a clinical rule based on the PSI to
guide the admission decision, treatment with
levoﬂoxacin, and practice guidelines. In this
study, implementation of a critical pathway
was associated with a reduction in hospital
stay, shorter duration of intravenous treatment
and a decrease in the number of admissions of
low-risk patients, without affecting mortality or
the incidence of complications. Carratala´ et al.
[77] performed an unblinded, randomised, con-
trolled clinical trial to determine whether out-
patient care of low-risk patients (according to
PSI score) with CAP treated with oral levoﬂ-
oxacin is as safe and effective as hospitalisation
and treatment with sequential intravenous and
oral levoﬂoxacin. They did not ﬁnd differences
in terms of successful outcomes between the
groups (83.6% in outpatients vs. 80.7% in
hospitalised patients; 95% CI, )7.1% to
12.9%). However, more outpatients were satis-
ﬁed with their overall care. No differences were
found with regard to mortality, medical com-
plications, and subsequent hospital admissions
between the groups. The authors concluded that
patients in PSI risk classes II and III can be
safely treated with levoﬂoxacin as outpatients in
the absence of respiratory failure, unstable
comorbid conditions requiring hospitalisation,
complicated pleural effusions, and social prob-
lems. Furthermore, this treatment will lead to
greater patient satisfaction.
CONCLUSIONS
Respiratory ﬂuoroquinolones, such as levoﬂoxa-
cin, are the only antimicrobials that are highly
active against S. pneumoniae, including macrolide-
resistant and penicillin-resistant strains,
H. inﬂuenzae, Legionella spp., and atypical agents.
Furthermore, these agents have a number of
advantageous pharmacokinetic properties, inclu-
ding high penetration into the lung and high oral
bioavailability [78,79], as well as a minimal
resistance potential and a good safety proﬁle.
Despite the difﬁculty of demonstrating differ-
ences between antimicrobials, recent studies
involving adult patients with CAP suggest that
levoﬂoxacin in monotherapy as compared with
other conventional treatments may be associated
with better clinical outcomes, including a faster
resolution of pneumonia symptoms and shorter
hospital stay. Thus, respiratory ﬂuoroquinolones
in general, and levoﬂoxacin in particular, should
be regarded as appropriate ﬁrst-line antimicrobi-
als for the monotherapeutic treatment of CAP in
outpatients and hospitalised patients, as well as in
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combination with a b-lactam in those patients
requiring ICU admission [4,14,29,80].
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